Last reviewed · How we verify
NCT05117047
A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma
trial testing liver resection in Long-term Effects of Cancer Treatment in 369 participants. Completed in 30 June 2021.
30 June 2017
Quick facts
| Lead sponsor | Chen Xiaoping |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 369 |
| Start date | 14 February 2015 |
| Primary completion | 30 June 2017 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- liver resection
Conditions studied
- Long-term Effects of Cancer Treatment — all drugs for Long-term Effects of Cancer Treatment →
Sponsor
Chen Xiaoping — full company profile →
Who can join
Adults 14 to 75, any sex, with Long-term Effects of Cancer Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators established three prospective cohorts of patients with BCLC stage 0-A HCC, based on different surgical approaches (open, laparoscopic and robotic). After 5 years of follow-up, the investigators used propensity score matching (PSM) to reduce selection bias and then compared the long-term oncological outcomes of the three different surgical approaches, which might provide high-level evidence in non-randomized observational studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05117047
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of liver resection
Trials testing the same drug.
- NCT06542926 — NON-COlorectal Liver METastases Undergoing Liver Resection · not yet recruiting
- NCT06311916 — Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. · Phase 4 · not yet recruiting
- NCT07030842 — Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma · completed
- NCT06988852 — FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis · Phase 2 · recruiting
- NCT05250843 — TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC · Phase 2, PHASE3 · unknown
Other recruiting trials for Long-term Effects of Cancer Treatment
Currently open trials in the same condition.
- NCT05005117 — Laparoscopic Approach for Emergency Colon Resection · NA · recruiting
Other Chen Xiaoping trials
Trials by the same sponsor.
- NCT06463444 — Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models · Phase 1 · recruiting
- NCT06420440 — Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model · Phase 2 · recruiting
- NCT06311916 — Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. · Phase 4 · not yet recruiting
- NCT06311942 — Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. · Phase 4 · recruiting
- NCT06311929 — Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05117047 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chen Xiaoping
- Last refreshed: 11 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05117047.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing